



## Rubinstein-Taybi syndrome

Rubinstein-Taybi syndrome is a condition characterized by short stature, moderate to severe intellectual disability, distinctive facial features, and broad thumbs and first toes. Additional features of the disorder can include eye abnormalities, heart and kidney defects, dental problems, and obesity. These signs and symptoms vary among affected individuals. People with this condition have an increased risk of developing noncancerous and cancerous tumors, including certain kinds of brain tumors. Cancer of blood-forming tissue (leukemia) also occurs more frequently in people with Rubinstein-Taybi syndrome.

Rarely, Rubinstein-Taybi syndrome can involve serious complications such as a failure to gain weight and grow at the expected rate (failure to thrive) and life-threatening infections. Infants born with this severe form of the disorder usually survive only into early childhood.

### Frequency

This condition is uncommon; it occurs in an estimated 1 in 100,000 to 125,000 newborns.

### Genetic Changes

Mutations in the *CREBBP* gene are responsible for some cases of Rubinstein-Taybi syndrome. The *CREBBP* gene provides instructions for making a protein that helps control the activity of many other genes. This protein, called CREB binding protein, plays an important role in regulating cell growth and division and is essential for normal fetal development. If one copy of the *CREBBP* gene is deleted or mutated, cells make only half of the normal amount of CREB binding protein. Although a reduction in the amount of this protein disrupts normal development before and after birth, researchers have not determined how it leads to the specific signs and symptoms of Rubinstein-Taybi syndrome.

Mutations in the *EP300* gene cause a small percentage of cases of Rubinstein-Taybi syndrome. Like the *CREBBP* gene, this gene provides instructions for making a protein that helps control the activity of other genes. It also appears to be important for development before and after birth. *EP300* mutations inactivate one copy of the gene in each cell, which interferes with normal development and causes the typical features of Rubinstein-Taybi syndrome. The signs and symptoms of this disorder in people with *EP300* mutations are similar to those with mutations in the *CREBBP* gene; however, studies suggest that *EP300* mutations may be associated with milder skeletal changes in the hands and feet.

Some cases of severe Rubinstein-Taybi syndrome have resulted from a deletion of genetic material from the short (p) arm of chromosome 16. Several genes, including the *CREBBP* gene, are missing as a result of this deletion. Researchers believe that the loss of multiple genes in this region probably accounts for the serious complications associated with severe Rubinstein-Taybi syndrome.

About half of people with Rubinstein-Taybi syndrome do not have an identified mutation in the *CREBBP* or *EP300* gene or a deletion in chromosome 16. The cause of the condition is unknown in these cases. Researchers predict that mutations in other genes are also responsible for the disorder.

## **Inheritance Pattern**

This condition is considered to have an autosomal dominant pattern of inheritance, which means one copy of the altered gene in each cell is sufficient to cause the disorder. Most cases result from new mutations in the gene and occur in people with no history of the disorder in their family.

## **Other Names for This Condition**

- Broad Thumb-Hallux Syndrome
- RSTS
- RTS

## **Diagnosis & Management**

### Genetic Testing

- Genetic Testing Registry: Rubinstein-Taybi syndrome  
<https://www.ncbi.nlm.nih.gov/gtr/conditions/C0035934/>

### Other Diagnosis and Management Resources

- GeneReview: Rubinstein-Taybi Syndrome  
<https://www.ncbi.nlm.nih.gov/books/NBK1526>
- MedlinePlus Encyclopedia: Rubinstein-Taybi syndrome  
<https://medlineplus.gov/ency/article/001249.htm>

### General Information from MedlinePlus

- Diagnostic Tests  
<https://medlineplus.gov/diagnostictests.html>
- Drug Therapy  
<https://medlineplus.gov/drugtherapy.html>
- Genetic Counseling  
<https://medlineplus.gov/geneticcounseling.html>

- Palliative Care  
<https://medlineplus.gov/palliativecare.html>
- Surgery and Rehabilitation  
<https://medlineplus.gov/surgeryandrehabilitation.html>

## **Additional Information & Resources**

### MedlinePlus

- Encyclopedia: Rubinstein-Taybi syndrome  
<https://medlineplus.gov/ency/article/001249.htm>
- Health Topic: Cancer  
<https://medlineplus.gov/cancer.html>
- Health Topic: Developmental Disabilities  
<https://medlineplus.gov/developmentaldisabilities.html>

### Genetic and Rare Diseases Information Center

- Rubinstein-Taybi syndrome  
<https://rarediseases.info.nih.gov/diseases/7593/rubinstein-taybi-syndrome>

### Educational Resources

- Disease InfoSearch: Rubinstein-Taybi syndrome  
<http://www.diseaseinfosearch.org/Rubinstein-Taybi+syndrome/6372>
- MalaCards: rubinstein-taybi syndrome  
[http://www.malacards.org/card/rubinstein\\_taybi\\_syndrome](http://www.malacards.org/card/rubinstein_taybi_syndrome)
- Orphanet: Rubinstein-Taybi syndrome  
[http://www.orpha.net/consor/cgi-bin/OC\\_Exp.php?Lng=EN&Expert=783](http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=783)

### Patient Support and Advocacy Resources

- National Organization for Rare Disorders (NORD)  
<https://rarediseases.org/rare-diseases/rubinstein-taybi-syndrome/>
- Resource list from the University of Kansas Medical Center  
<http://www.kumc.edu/gec/support/rubinste.html>

### GeneReviews

- Rubinstein-Taybi Syndrome  
<https://www.ncbi.nlm.nih.gov/books/NBK1526>

### ClinicalTrials.gov

- ClinicalTrials.gov  
<https://clinicaltrials.gov/ct2/results?cond=%22rubinstein-taybi+syndrome%22>

## Scientific Articles on PubMed

- PubMed  
<https://www.ncbi.nlm.nih.gov/pubmed?term=%28Rubinstein-Taybi+Syndrome%5BMAJR%5D%29+AND+%28Rubinstein-Taybi+syndrome%5BTIAB%5D%29+AND+english%5BIa%5D+AND+human%5Bmh%5D+AND+%22last+1800+days%22%5Bdp%5D>

## OMIM

- RUBINSTEIN-TAYBI SYNDROME 1  
<http://omim.org/entry/180849>

## **Sources for This Summary**

- Bartholdi D, Roelfsema JH, Papadia F, Breuning MH, Niedrist D, Hennekam RC, Schinzel A, Peters DJ. Genetic heterogeneity in Rubinstein-Taybi syndrome: delineation of the phenotype of the first patients carrying mutations in EP300. *J Med Genet.* 2007 May;44(5):327-33. Epub 2007 Jan 12.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/17220215>  
*Free article on PubMed Central:* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597984/>
- Bartsch O, Rasi S, Delicado A, Dyack S, Neumann LM, Seemanová E, Volleth M, Haaf T, Kalscheuer VM. Evidence for a new contiguous gene syndrome, the chromosome 16p13.3 deletion syndrome alias severe Rubinstein-Taybi syndrome. *Hum Genet.* 2006 Sep;120(2):179-86. Epub 2006 Jun 17.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/16783566>
- Bartsch O, Schmidt S, Richter M, Morlot S, Seemanová E, Wiebe G, Rasi S. DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein-Taybi syndrome (RSTS) and in another patient with incomplete RSTS. *Hum Genet.* 2005 Sep;117(5):485-93. Epub 2005 Jul 14.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/16021471>
- Bentivegna A, Milani D, Gervasini C, Castronovo P, Mottadelli F, Manzini S, Colapietro P, Giordano L, Atzeri F, Divizia MT, Uzielli ML, Neri G, Bedeschi MF, Faravelli F, Selicorni A, Larizza L. Rubinstein-Taybi Syndrome: spectrum of CREBBP mutations in Italian patients. *BMC Med Genet.* 2006 Oct 19;7:77.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/17052327>  
*Free article on PubMed Central:* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1626071/>
- Coupry I, Roudaut C, Stef M, Delrue MA, Marche M, Burgelin I, Taine L, Cruaud C, Lacombe D, Arveiler B. Molecular analysis of the CBP gene in 60 patients with Rubinstein-Taybi syndrome. *J Med Genet.* 2002 Jun;39(6):415-21.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/12070251>  
*Free article on PubMed Central:* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1735143/>
- GeneReview: Rubinstein-Taybi Syndrome  
<https://www.ncbi.nlm.nih.gov/books/NBK1526>
- Hallam TM, Bourtchouladze R. Rubinstein-Taybi syndrome: molecular findings and therapeutic approaches to improve cognitive dysfunction. *Cell Mol Life Sci.* 2006 Aug;63(15):1725-35. Review.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/16786226>
- Hennekam RC. Rubinstein-Taybi syndrome. *Eur J Hum Genet.* 2006 Sep;14(9):981-5. Epub 2006 Jul 26. Review.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/16868563>

- Roelfsema JH, White SJ, Ariyürek Y, Bartholdi D, Niedrist D, Papadia F, Bacino CA, den Dunnen JT, van Ommen GJ, Breuning MH, Hennekam RC, Peters DJ. Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. *Am J Hum Genet.* 2005 Apr;76(4):572-80. Epub 2005 Feb 10.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/15706485>  
*Free article on PubMed Central:* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1199295/>
  - Wiley S, Swayne S, Rubinstein JH, Lanphear NE, Stevens CA. Rubinstein-Taybi syndrome medical guidelines. *Am J Med Genet A.* 2003 Jun 1;119A(2):101-10. Review.  
*Citation on PubMed:* <https://www.ncbi.nlm.nih.gov/pubmed/12749047>
- 

Reprinted from Genetics Home Reference:

<https://ghr.nlm.nih.gov/condition/rubinstein-taybi-syndrome>

Reviewed: January 2007

Published: July 18, 2017

Lister Hill National Center for Biomedical Communications  
U.S. National Library of Medicine  
National Institutes of Health  
Department of Health & Human Services